A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co failed to warn that its osteoporosis ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

(Reuters) - A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Shares of Bicara Therapeutics—a biopharmaceutical company backed by Indian billionaire Kiran Mazumdar-Shaw—surged about 42% ...

A letter from the FDA rejecting Merck Sharpe & Dohme Corp.'s proposed label warning that its osteoporosis drug Fosamax could cause stress fractures doesn’t preempt state law claims alleging the ...

Merck (MRK) ended the recent trading session at $117.17, demonstrating a -0.05% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.19%.

This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...